Nautilus Biotechnology (NASDAQ:NAUT) Issues Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Nautilus Biotechnology (NASDAQ:NAUT) announced its quarterly earnings data on Monday. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.03, FiscalAI reports. The firm had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.25 million.

Nautilus Biotechnology Trading Down 1.8%

Shares of NASDAQ NAUT opened at $1.66 on Tuesday. Nautilus Biotechnology has a 12-month low of $0.62 and a 12-month high of $4.31. The company has a market cap of $210.95 million, a price-to-earnings ratio of -3.61 and a beta of 0.80. The stock’s 50 day simple moving average is $2.13 and its 200 day simple moving average is $2.45.

Insiders Place Their Bets

In other Nautilus Biotechnology news, major shareholder Ah Equity Partners Bio Ii, L.L sold 5,000,000 shares of the firm’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $2.35, for a total value of $11,750,000.00. Following the sale, the insider directly owned 971,885 shares in the company, valued at approximately $2,283,929.75. This trade represents a 83.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 41.10% of the stock is owned by corporate insiders.

Institutional Trading of Nautilus Biotechnology

Several hedge funds have recently bought and sold shares of the company. Millennium Management LLC grew its position in Nautilus Biotechnology by 5.4% in the 4th quarter. Millennium Management LLC now owns 1,019,996 shares of the company’s stock worth $1,989,000 after purchasing an additional 52,448 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Nautilus Biotechnology by 1.3% during the fourth quarter. Geode Capital Management LLC now owns 560,909 shares of the company’s stock worth $1,094,000 after buying an additional 7,307 shares during the period. Corient Private Wealth LLC boosted its position in shares of Nautilus Biotechnology by 860.0% during the second quarter. Corient Private Wealth LLC now owns 435,350 shares of the company’s stock worth $316,000 after buying an additional 390,000 shares during the period. Jacobs Levy Equity Management Inc. grew its holdings in Nautilus Biotechnology by 18.1% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 301,012 shares of the company’s stock worth $254,000 after buying an additional 46,153 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in Nautilus Biotechnology by 152.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 297,437 shares of the company’s stock worth $580,000 after buying an additional 179,721 shares in the last quarter. 50.71% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Nautilus Biotechnology in a research report on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Nautilus Biotechnology currently has a consensus rating of “Hold” and an average target price of $4.00.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.